Tue, Sep 30, 2014, 6:04 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Boston Scientific Corporation Message Board

  • buzzoelvis buzzoelvis Apr 19, 2012 4:23 PM Flag

    Bsx Under valued, take out still alive!

    Bsx with EP slowly healing and litigation fading at under $6 is a steal. Growth, any growth brings tremendous leverage in a terribly difficult environment, Bard, Covidien, even Medtronic could be a suitor. Then Abbott will be forced to step forward with their partner St Judes.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • As of right now, Bard has a market cap of $8.26 billion and BSX has a market cap of $8.49 billion. Bard's annual revenue is less than $3 billion, and BSX's annual revenue is around $7.5 billion. You really think a significantly smaller company like Bard is going to buy BSX?

      You really think the FTC, SEC, and the EU would allow MDT to buy BSX? No anti-trust concerns with stents and ICDs??!!

      You really think the FTC, SEC, and the EU would allow ABT and STJ to buy BSX? No anti-trust concerns with stents and ICDs??!!

      BSX didn't grow revenue, if you actually read their revenue report. Why would anybody buy a sinking ship?

      As reported today:
      "US CRM sales were down 14% this quarter, worse than St. Jude's (-7%) performance (and Medtronic (MDT ) won't report for a while). ICD revenue fell 12% (St. Jude's fell 2%), indicating that BSX continues to lose share despite some controversy with St. Jude's leads."

      "Global sales of coronary stent system (within Interventional Cardiology) at $387 million declined 5.8% due to disappointing performance from both drug-eluting stents (“DES”) that declined 4.2% to $363 million and bare-metal stents that plunged 20% to $24 million."

11.81-0.11(-0.92%)Sep 30 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.